Research Papers:

Synthetic low-density lipoprotein (sLDL) selectively delivers paclitaxel to tumor with low systemic toxicity

Hai-Tao Su, Xin Li, De-Sheng Liang and Xian-Rong Qi _

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:51535-51552. https://doi.org/10.18632/oncotarget.10493

Metrics: PDF 1779 views  |   HTML 2541 views  |   ?  


Hai-Tao Su1, Xin Li1, De-Sheng Liang1, Xian-Rong Qi1,2

1Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery System, School of Pharmaceutical Sciences, Peking University, Beijing, 100191, PR China

2State Key Laboratory of Natural and Biomimetic Drugs, Beijing, 100191, PR China

Correspondence to:

Xian-Rong Qi, email: [email protected]

Keywords: synthetic low-density lipoprotein (sLDL), biomimetic, PTX-alpha linolenic acid (PALA), anti-tumor efficacy, low systemic toxicity

Received: April 07, 2016     Accepted: June 30, 2016     Published: July 08, 2016


Low density lipoprotein (LDL), which is a principal carrier for the delivery of cholesterol, has been used as a great candidate for the delivery of drugs to tumor based on the great requirements for cholesterol of many cancer cells. Mimicking the structure and composition of LDL, we designed a synthetic low-density lipoprotein (sLDL) to encapsulate paclitaxel-alpha linolenic acid (PALA) for tumor therapy. The PALA loaded sLDL (PALA-sLDL) and PALA-loaded microemulsion (PALA-ME, without the binding domain for LDLR) displayed uniform sizes with high drug loading efficiency (> 90%). In vitro studies demonstrated PALA-sLDL exhibited enhanced cellular uptake capacity and better cytotoxicity to LDLR over-expressed U87 MG cells as compared to PALA-ME. The uptake mechanisms of PALA-sLDL were involved in a receptor mediated endocytosis and macropinocytosis. Furthermore, the in vivo biodistribution and tumor growth inhibition studies of PALA-sLDL were investigated in xenograft U87 MG tumor-bearing mice. The results showed that PALA-sLDL exhibited higher tumor accumulation than PALA-ME and superior tumor inhibition efficiency (72.1%) compared to Taxol® (51.2%) and PALA-ME (58.8%) but with lower toxicity. These studies suggested that sLDL is potential to be used as a valuable carrier for the selective delivery of anticancer drugs to tumor with low systemic toxicity.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10493